-Atrogin-1, a musclespecific E3 ligase, targets MyoD for degradation through the ubiquitin-proteasome-mediated system. Myostatin, a member of the transforming growth factor-␤ superfamily, potently inhibits myogenesis by lowering MyoD levels. While atrogin-1 is upregulated by myostatin, it is currently unknown whether atrogin-1 plays a role in mediating myostatin signaling to regulate myogenesis. In this report, we have confirmed that atrogin-1 increasingly interacts with MyoD upon recombinant human myostatin (hMstn) treatment. The absence of atrogin-1, however, led to elevated MyoD levels and permitted the differentiation of atrogin-1 Ϫ/Ϫ primary myoblast cultures despite the presence of exogenous myostatin. Furthermore, inactivation of atrogin-1 rescued myoblasts from growth inhibition by hMstn. Therefore, these results highlight the central role of atrogin-1 in regulating myostatin signaling during myogenesis. Currently, there are only two known targets of atrogin-1. Thus, we next characterized the associated proteins of atrogin-1 in control and hMstn-treated C2C12 cell cultures by stably expressing tagged atrogin-1 in myoblasts and myotubes, and sequencing the coimmunoprecipitated proteome. We found that atrogin-1 putatively interacts with sarcomeric proteins, transcriptional factors, metabolic enzymes, components of translation, and spliceosome formation. In addition, we also identified that desmin and vimentin, two components of the intermediate filament in muscle, directly interacted with and were degraded by atrogin-1 in response to hMstn. In summary, the muscle wasting effects of the myostatinatrogin-1 axis are not only limited to the degradation of MyoD and eukaryotic translation initiation factor 3 subunit f, but also encompass several proteins that are involved in a wide variety of cellular activities in the muscle. myostatin; atrogin-1; MyoD; sarcomeric proteins; ubiquitin-mediated proteolysis; skeletal muscle wasting SKELETAL MUSCLE WASTING is the progressive loss of protein content due to a combination of both increased protein degradation and decreased protein synthesis (10, 20, 24, 54) . Ubiquitin-proteasome-dependent degradation is the predominating proteolysis system that is activated during skeletal muscle wasting (22). Proteins are selectively targeted to the ubiquitinproteasome system by several ubiquitin E3 ligases. Atrogin-1 (muscle atrophy F-box or MAFbx) and muscle RING Finger 1 (MuRF1) are two E3 ligases found exclusively in skeletal muscles, and they are the two foremost mediators of skeletal muscle wasting (3, 25). The increased expression of atrogin-1 and MuRF1 in skeletal muscles is observed during immobilization, denervation, hindlimb suspension, and glucocorticoid (dexamethasone) treatment (3, 4, 10, 47, 50). Cachectic cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-␣ (TNF-␣), interferon-␥ (IFN-␥), and the transforming growth factor-␤ superfamily growth factor, myostatin, are also shown to be associated with increased atrogin-1 and MuRF1 in the muscle (3, 12, 29, 34, 49, 51) .
SKELETAL MUSCLE WASTING is the progressive loss of protein content due to a combination of both increased protein degradation and decreased protein synthesis (10, 20, 24, 54) . Ubiquitin-proteasome-dependent degradation is the predominating proteolysis system that is activated during skeletal muscle wasting (22) . Proteins are selectively targeted to the ubiquitinproteasome system by several ubiquitin E3 ligases. Atrogin-1 (muscle atrophy F-box or MAFbx) and muscle RING Finger 1 (MuRF1) are two E3 ligases found exclusively in skeletal muscles, and they are the two foremost mediators of skeletal muscle wasting (3, 25) . The increased expression of atrogin-1 and MuRF1 in skeletal muscles is observed during immobilization, denervation, hindlimb suspension, and glucocorticoid (dexamethasone) treatment (3, 4, 10, 47, 50) . Cachectic cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-␣ (TNF-␣), interferon-␥ (IFN-␥), and the transforming growth factor-␤ superfamily growth factor, myostatin, are also shown to be associated with increased atrogin-1 and MuRF1 in the muscle (3, 12, 29, 34, 49, 51) .
Atrogin-1 contains an F-box domain that is characteristic of the SCF class of E3 ligases (25) . SCF complexes are composed of Skp1, Cullin (Cul1), a RING finger protein, and the F-box protein (25, 26) . The F-box protein binds and polyubiquitinates the substrate, which results in its degradation through the ubiquitin-proteasome system (25) . The well-known molecular substrates of atrogin-1 are MyoD, a myogenic regulatory factor, calcineurin, and eukaryotic translation initiation factor 3 subunit f (eIF3-f), a critical component in protein translation (16) . Recently, we have demonstrated that atrogin-1 also interacts and targets myosin heavy chain (Myh) and myosin light chain isoforms in response to myostatin-induced skeletal muscle atrophy (35, 36) . The upregulation of atrogin-1 by myostatin is mediated by the FoxO1 transcription factor via Smad3 signaling (35) . Furthermore, dexamethasone injections resulted in the overexpression of atrogin-1 in skeletal muscle through the Akt/FoxO3 pathway (48) . Upon denervation, however, the expression of atrogin-1 was shown to be regulated by myogenin (45) .
Although it is well documented that myostatin-induced upregulation of atrogin-1 leads to skeletal muscle wasting both in vitro and in vivo, the full extent of the substrates targeted by atrogin-1 have yet to be defined. Thus, we have coimmunoprecipitated atrogin-1 complex in myoblasts and myotubes exposed to human myostatin (hMstn) and identified the associated proteins by nano-LC-MS/MS. Herein, we demonstrate that atrogin-1 interacts with several substrates including sarcomeric proteins, transcriptional factors, as well as components involved in protein synthesis, and the spliceosome. Furthermore, our results demonstrate that myostatin promotes the interaction of MyoD, with atrogin-1, and absence of the muscle-specific E3 ligase allowed the proliferation and differentiation of myoblasts to proceed even in the presence of exogenous myostatin. In addition to MyoD, we also determined that desmin (Des) and vimentin (Vim) interacted with atrogin-1, and their degradation by hMstn was dependent on atrogin-1.
MATERIALS AND METHODS
Cell culture and treatments. Murine C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were cultured according to the previously published protocol (42) . Recombinant hMstn protein was expressed and purified from Escherichia coli according to the protocol described by McFarlane et al. (43) . C2C12 myoblasts and myotubes were treated with hMstn at a concentration of 5 g/ml for 24 h. The peak of MyoD protein level in C2C12 myoblasts was detected at 48 h in the differentiation medium by immunoblotting. Hence, C2C12 myoblasts were allowed to differentiate for 24 h in DMEM with 2% horse serum and 1% penicillin-streptomycin, then hMstn was added and the cells were incubated for an additional 24 h. To inhibit the proteasome-degradation system, 100 nM of epoximicin (Epox) (Sigma) was added to the C2C12 cell cultures 12 h before protein collection.
Animal care. Dr. Esther Latres (Regeneron Pharmaceuticals) kindly gifted MAFbx Ϫ/Ϫ (atrogin-1 Ϫ/Ϫ ) mice. Wild-type mice (C57BL/6) were obtained from the Centre for Animal Resources (National University of Singapore, Singapore). All experiments were performed according to the approved protocols of the Institutional Animal Ethics Committee of the Nanyang Technological University of Singapore. For primary myoblast culture, mice were terminated just before the commencement of the experiment by CO 2 asphyxiation, according to the Institutional Animal Care and Use Committee rules and regulations (Singapore).
Primary myoblast culture and myoblast proliferation assay. Primary myoblasts were isolated according to the previously described protocol (39) . Proliferation was assessed using the methylene blue photometric end-point assay. Myoblasts were seeded in 96-well plates at a density of 1,000 cells/well and incubated at 37°C and 5% CO 2. Proliferating primary myoblasts were fixed at 24-h intervals using 100 l of fixative (10% formaldehyde, 0.9% NaCl). The fixative was removed and cells were washed with PBS twice. Cells were incubated with 100 l methylene blue stain (1% methylene blue, 0.01 M sodium tetraborate, pH 8.5) at room temperature for 30 min. After removal of the methylene blue stain, cells were washed four times with 0.01 M sodium tetraborate, pH 8.5, and 200 l of 0.1 M HCl:70% ethanol (1:1) was added into each well. The absorbance was read with a microplate reader at 655 nm. The absorbance of the cells is directly proportional to final cell number.
Measurement of myotube number and fusion index. To assess the ability of hMstn to inhibit the differentiation of atrogin-1 Ϫ/Ϫ and atrogin-1 ϩ/ϩ primary murine myoblasts, the cells were first seeded on Thermanox coverslips (Nunc, Roskilde, Denmark) at a density of 25,000 cells/cm 2 . Primary myoblasts were induced to differentiate in DMEM with 2% horse serum and 1% penicillin-streptomycin in the Fig. 1 . Atrogin-1 association with MyoD increases upon myostatin treatment. A: immunoblot (IB) analysis of MyoD from total lysates collected from differentiating C2C12 myoblasts (48 h) treated with or without recombinant human myostatin (hMstn) for 24 h. MyoD was immunoprecipitated (IP) and subjected to IB analysis using a pan-specific antiubiquitin antibody. Mobility shift of MyoD protein as a result of myostatin treatment is indicative of polyubiquitination. Tubulin levels were assessed to ensure equal loading. B: densitometry analysis of IB from A showing relative protein levels in arbitrary units (AU). Values are means Ϯ SD; n ϭ 3. *P Ͻ 0.01. C: immunoblot analysis of MyoD and atrogin-1 in differentiating C2C12 myoblasts treated with or without hMstn and the proteasome inhibitor epoximicin (Epox). Tubulin levels were assessed to ensure equal loading. D: immunoblot analysis using anti-protein-A (horseradish peroxidase-conjugate) antibody to confirm the protein expression of COOH-terminal tagged atrogin-1 construct (atrogin-1-CTAP) and empty vector constructs stably expressed in C2C12 myoblasts. E: coimmunoprecipitation (co-IP) analysis of atrogin-1-CTAP protein lysate from differentiating C2C12 myotubes treated with or without hMstn protein. MyoD expression levels were detected in the whole cell lysate (input) and the co-IP extracts. F: densitometry analysis of IB from D showing the relative protein levels for MyoD from the input (left) and after the pull down (right) in arbitrary units. Values are means Ϯ SD; n ϭ 3. *P Ͻ 0.01. presence or absence of hMstn. At the indicated time points, the cultures were fixed with ethanol:formaldehyde:glacial acetic acid (20:2:1) and stained with Gill's hematoxylin and 1% eosin. Myotubes containing equal or more than three myonuclei were considered for measuring the myotube number using the Image-Pro Plus analysis software package (MediaCybernetics, Bethesda, MD). Fusion index was determined by counting the number of nuclei within myotubes over the total number of nuclei (represented as percentage). Myotube number and fusion index were assessed in 10 random images taken from 3 coverslips per treatment.
Tandem affinity purification, nano-LC-MS/MS analysis, and coimmunoprecipitation.
The cDNA of atrogin-1 (NM_026346) was PCR amplified as a BamH1 and EcoR1 fragment and cloned into pZome1C (atrogin-1 CTAP) and pZome1N (atrogin-1 NTAP) vector using standard molecular biological techniques with the following set of primers: COOH-terminal atrogin-1, forward primer, GGA TCC ATG CCG TTC CTT, and reverse primer, GGA TCC GAA CTT GAA CAA ATT GA; NH 2-terminal-atrogin-1, forward primer, GAA TTC ATG CCG TTC CTT G, and reverse primer, GAA TTC TCA GAA CTT GAA CAA ATT GA. Myoblasts that were stably express- Fig. 2 . Atrogin-1 blockade prevents MyoD protein degradation. A: immunoblot analysis of myosin heavy chain (Myh) and MyoD protein levels in both differentiating atrogin-1 ϩ/ϩ and atrogin-1 Ϫ/Ϫ primary myoblasts in control (Ctrl) or hMstn treatment (0, 24, 48, and 72 h time points). Primary myoblasts were isolated from 6-wk-old wild-type (atrogin-1 ϩ/ϩ ) and atrogin-1 knockout (atrogin-1 Ϫ/Ϫ ) mice. B: relative levels of MyoD in arbitrary units ascertained from the corresponding IB in A. C: myotube number was quantified from hematoxylin and eosin (H&E)-stained micrographs of atrogin-1 ϩ/ϩ and atrogin-1 Ϫ/Ϫ cells treated with hMstn or Ctrl using Image Pro Plus. Values are means Ϯ SD; *P Ͻ 0.01. D: fusion index assessed by counting total number of nuclei and myonuclei from H&E-stained micrographs of 72 h differentiating atrogin-1 ϩ/ϩ and atrogin-1 Ϫ/Ϫ myotubes in the presence or absence of hMstn using Image Pro Plus. Values are means Ϯ SD; *P Ͻ 0.01. E: proliferation of atrogin-1 ϩ/ϩ and atrogin-1 Ϫ/Ϫ primary myoblasts exposed to hMstn. Myoblast proliferation was measured by the methylene blue photometric end-point assay. Absorbance (655 nm) is directly proportional to cell number, and 0, 24, 48, and 72 h represent the time of myoblasts in culture. Values are means Ϯ SD; n ϭ 16. *P Ͻ 0.01.
ing atrogin-1-CTAP and atrogin-1-NTAP plasmids were differentiated into myotubes and were treated with 5 g/ml hMstn for 24 h. The myotubes were lysed, and 5 mg of protein extracted from control and tagged atrogin-1-expressing C2C12 myotubes were subjected to tandem affinity purification according to previously published protocols (9, 35, 56, 58) . Equal amounts of affinity-purified protein were resolved on 4 -12% NuPAGE gel and stained using Silver Stain Plus (Bio-Rad) according to the manufacturer's recommended protocol. Specific bands and/or regions of interest were excised from the gel and digested in situ with modified porcine trypsin (Promega). Tryptically digested samples were purified, concentrated, and then analyzed with nano-LC-MS/MS (Thermo Fisher Scientific). The raw data were converted to mascot generic format using an in-house program (27) and were searched against the International Protein Index (IPI) mouse protein sequence database(version 3.34; 69,164 sequences and 29,064,824 residues).
Data analysis. Data were generated from two independent experiments. The resulting data set was auto bias corrected and background corrected by the Paragon algorithm. The results of the combined data and the two independent experimental data were exported from ProteinPilot as Protein Summary reports in Microsoft Excel file format. Results were further analyzed using the online Gene Ontology (GO) software (available at http://david.abcc.ncifcrf.gov). Subcellular and functional categories were based on the annotations of GO using the Mouse Genome Informatics (MGI) GO_Slim Chart Tool (available from MGI).
Immunoblot analysis. C2C12 myoblasts or myotubes or primary cultures were resuspended in protein lysis buffer [50 mM Tris, pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% NP-40, Complete protease inhibitor cocktail (Roche), 2 mM NaF and 1 mM Na 3VO4, 1 mM PMSF], incubated for 15 min and then centrifuged at 12,000 rpm for 10 min at 4°C. Proteins were quantified using Bradford reagent (Bio-Rad). A total of 15 g of protein lysate were separated on a 4 -12% pre-cast gel (Invitrogen), and then transferred to a nitrocellulose membrane. The membranes were then blocked overnight at 4°C in 5% milk in 1ϫ Tris-buffered saline and Tween 20 (TBST), and then incubated with primary antibodies for 3 h with 5% milk in 1ϫ TBST. The membranes were washed in 1ϫ TBST for 5 min (5 times) Fig. 3 . Atrogin-1 increasingly interacts with components from the nucleus and cytosol in C2C12 myoblasts upon myostatin exposure. A: immunoblot analysis of atrogin-1 in proliferating C2C12 myoblasts in the presence or absence of hMstn. B: the image represents a silver-stained 4 -12% NuPAGE gel of the purified atrogin-1-CTAP protein complex from C2C12 myoblasts treated with or without hMstn. C: Venn diagram highlights the number of atrogin-1-associated proteins that were common or unique to the control and hMstn-treated C2C12 myoblasts. The total number of atrogin-1-interacting proteins in the control was 31, whereas 65 proteins were identified for myostatin-treated C2C12 myoblasts. D and E: atrogin-1-associated proteins identified from untreated control C2C12 myoblasts (D) and hMstn-treated C2C12 myoblasts (E) classified according to their subcellular location. Subcellular localization was classified by MGI Gene Ontology (GO)_Slim Chart Tool. ER, endoplasmic reticulum. 
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Rtn2 isoform 1 of reticulon-2 ϩ and then incubated with either goat anti-mouse IgG-horseradish peroxidase (HRP) conjugate or goat anti-rabbit IgG-HRP conjugate in 5% milk in 1ϫ TBST for 1 h at room temperature. The washes were repeated for 5 min (5 times), before HRP activity was detected using Western Lightning Chemiluminescence Reagent Plus (PerkinElmer). Membranes were exposed to XAR film (Kodak), and the developed films were scanned and analyzed using Quantity One imaging software (Bio-Rad). The antibodies used in this study were atrogin-1, kindly gifted by Dr. Esther Latres, and MyoD (no. sc-304), ubiquitin (no. sc-32322), Des (no. sc-70961), and Vim (no. sc-8017), purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Immunoprecipitation. Immunoprecipitation was performed according to a previously described protocol (35) . Briefly, C2C12 myoblasts were differentiated for 72 h and were then incubated for an additional 24 h in the absence or presence of hMstn (5 g/ml). The cultures were then harvested in 1 ml of RIPA buffer (50 mM NaF, 0.5% Na deoxycholate, 0.1% SDS, 1% IGEPAL, 1.5 mM Na 3VO4, and complete protease inhibitor) and centrifuged to remove cell debris. Bradford reagent (Bio-Rad, Hercules, CA) was used to estimate total protein content to ensure equal loading. Before immunoprecipitation, 250 g of total protein was precleared using 25 l of a 50% Protein A-agarose slurry for 1 h at 4°C. Immunoprecipitation was performed by incubating the precleared lysate with 2 g of primary antibody for 2 h at 4°C. Protein A-agarose (Invitrogen) (50 l of 50%), washed twice with RIPA buffer, was added for 1 h at 4°C, followed by centrifugation to pellet immunoprecipitated complexes. Pellets were washed four times with cold PBS, resuspended in 50 l of 1ϫ NuPAGE sample buffer (Invitrogen), and boiled for 5 min. Immunoprecipitation samples were fractionated by SDS-PAGE and transferred to nitrocellulose membrane by electroblotting for subsequent immunoblotting analysis using the specific antibodies against the protein of interest.
Statistical analysis. One-way ANOVA and two-tailed Student's t-test were performed for statistical significance measurements. Statistical significance was set at P Ͻ 0.01. The values are represented as means Ϯ SD.
RESULTS

Atrogin-1 association with MyoD increases upon myostatin treatment.
We have previously demonstrated that myostatin modulates the differentiation of myoblasts by reducing MyoD (43, 52) . Additionally, we have also shown that myostatin upregulates atrogin-1, a muscle-specific E3 ligase (35, 36, 42) . Although atrogin-1 ubiquitinates and targets MyoD for degradation (30, 53) , it is currently unclear whether myoblast exposure to exogenous recombinant hMstn would result in the degradation of MyoD through atrogin-1. The incubation of differentiating C2C12 myoblasts with hMstn for 24 h expectedly resulted in the reduction of MyoD protein levels compared with the untreated differentiating C2C12 myoblasts (Fig. 1A) . Additionally, the degradation of MyoD induced by hMstn in differentiating C2C12 myoblasts was dependent on the ubiquitin-proteasome pathway. To detect the ubiquitinated MyoD, we immunoprecipitated lysates obtained from differentiating C2C12 myoblasts exposed to hMstn with MyoD antibody (Fig. 1, A and B). We also observed a denser band shift in the MyoD-immunoprecipitated lysates from hMstn-treated differentiating C2C12 myoblasts compared with the control, suggesting that MyoD was increasingly polyubiquitinated during hMstn treatment (Fig. 1, A and B) . Furthermore, MyoD degradation induced by hMstn was inhibited by the addition of Epox, a proteasome inhibitor (Fig. 1C) . Atrogin-1 expression levels upon hMstn treatment in differentiating C2C12 myoblasts were elevated compared with the control (Fig. 1C) . Moreover, hMstn treatment with Epox also resulted in the upregulation of atrogin-1 (Fig. 1C) .
To study the interaction between atrogin-1 and MyoD in response to hMstn treatment, we synthesized a COOH-terminal tagged atrogin-1 construct (atrogin-1-CTAP) that was amenable for tandem affinity purification. Next, atrogin-1-CTAP was stably expressed in C2C12 myoblasts (Fig. 1D) . A MyoD immunoblot of the purified atrogin-1-CTAP complex isolated from differentiating C2C12 myoblasts treated with hMstn demonstrated elevated amounts of MyoD compared with the untreated control (Fig. 1E) . Note that the expression of the atrogin-1-CTAP vector was unchanged in both control and hMstn-treated cells, confirming that the increased association with MyoD was not a result of increased atrogin-1-CTAP (Fig. 1, E and F) .
Atrogin-1 blockade prevents MyoD protein degradation. MyoD is a critical myogenic regulatory factor that modulates the differentiation of myoblasts into myotubes. The myostatin treatment, however, significantly reduces the levels of MyoD and thus impairs myogenesis (32, 38, 55) . As shown in Fig. 2 , A and B, treatment of differentiating wild-type (atrogin-1 ϩ/ϩ ) primary myoblasts with hMstn resulted in the expected reduction in MyoD protein levels (Fig. 2, A and B) . Furthermore, hMstn treatment resulted in the progressive loss of Myh protein levels in atrogin-1 ϩ/ϩ primary myoblasts ( Fig. 2A) . We next examined whether the removal of atrogin-1 prevented hMstnmediated MyoD degradation. Indeed, the MyoD levels in differentiating atrogin-1 Ϫ/Ϫ primary myoblasts treated with hMstn were comparable to the untreated differentiating atrogin-1 ϩ/ϩ primary myoblasts (Fig. 2, A and B) . Furthermore, hMstn treatment of atrogin-1 Ϫ/Ϫ differentiating primary (Fig. 2A) . In addition, atrogin-1 Ϫ/Ϫ primary myoblasts displayed a rescue of myotube number despite the presence of hMstn compared with atrogin-1 ϩ/ϩ myoblasts similarly exposed to hMstn (Fig. 2C) . Furthermore, differentiating atrogin-1 Ϫ/Ϫ primary myoblasts incubated with hMstn demonstrated a greater fusion index compared with atrogin-1 ϩ/ϩ myoblasts treated with hMstn (Fig. 2D) . We also investigated the effect of hMstn on the proliferation of atrogin-1 ϩ/ϩ and atrogin-1 Ϫ/Ϫ primary myoblasts. Expectedly, hMstn suppressed atrogin-1 ϩ/ϩ myoblast growth at 48 and 72 h (Fig. 2E) . Atrogin-1 Ϫ/Ϫ primary myoblasts were slightly susceptible to the limiting effects of hMstn treatment, though the difference was insignificant compared with the atrogin-1 ϩ/ϩ (wild-type control) (Fig. 2E) . Nevertheless, these results suggest that atrogin-1 is a critical component in modulating both myoblast proliferation and differentiation.
Atrogin-1 associates with several components involved in protein synthesis and spliceosome formation in C2C12 proliferating myoblasts. After establishing the role of atrogin-1 in orchestrating muscle proliferation and growth, we then aimed to characterize the molecular targets of the muscle-specific E3 ligase. According to the published literature, there are only two established targets of atrogin-1, MyoD and eIF3-f (16, 17, 31, 53) . To identify additional interactors of atrogin-1 in C2C12 myoblasts and whether these atrogin-1-associated proteins varied upon the addition of hMstn, we purified the atrogin-1-CTAP complex stably expressed in control C2C12 myoblasts or that were treated with hMstn. The atrogin-1-CTAP complex was screened for interacting proteins by nano-LC-MS/MS (Fig. 3B and Table 1 ). It is also important to note that endogenous levels of atrogin-1 were elevated in C2C12 myoblasts treated with hMstn (Fig. 3A) .
We detected 31 atrogin-1-associated proteins in the untreated myoblasts (Fig. 3C) . When myoblasts were treated by hMstn, however, 65 proteins interacted with atrogin-1, which was approximately double the number of associated proteins found in the control (Fig. 3C and Table 1 ). Out of all the atrogin-1-associated proteins, 18 proteins were common to both control and hMstn-induced conditions (Fig. 3C ). An additional 13 proteins associated with atrogin-1 only in control conditions, whereas 47 new proteins interacted with atrogin-1 in response to hMstn treatment (Fig. 3C) .
The atrogin-1-associated proteins appear to be diverse, ranging from nuclear and cytosolic proteins to mitochondrial and plasma membrane components (Fig. 3, D and E, and Tables 2 and 3) . Notably, the atrogin-1-CTAP coimmunoprecipitated complex in both the control and the hMstn-treated conditions revealed a pronounced amount of nuclear localized proteins associated with the muscle-specific E3 ligase (Fig. 3, D and E) . Among the nuclear localized atrogin-1-associated proteins, we observed the interaction of the MyoD transcription factor in the control and hMstn-induced conditions (Table 1) .
Using String software (version 8.3), we organized the list of atrogin-1-associated proteins according to their known and predicted protein interactions (Fig. 4, A and B) . Apart from the expected result of atrogin-1 clustering with Skp1 and Cul1, which together form the functional E3 ligase, the most striking cluster found in the control, which was exaggerated during hMstn treatment, was the protein synthesis components (Fig. 4,   A and B) . Specifically, we observed the association of subunits of eIF2/3/4 initiation complexes, elongation factors, such as Eef1 and Eef2, as well as ribosomal proteins, including Rpl14, Rpl22, and Rpl7 (Fig. 4, A and B) . Another cluster of interest was a set of proteins involved in mRNA splicing, such as Snrnp70 and Sfrs4 (Fig. 4, A and B) . KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis of the coimmunoprecipitated atrogin-1 complex further identified the putative association of spliceosome and protein synthesis machinery (data not shown).
Atrogin-1 interacts with sarcomeric, structural, and mitochondrial proteins in C2C12 myotubes. The negative impact of myostatin is not only limited to myoblast proliferation and differentiation, as the growth factor also induces the wasting of differentiated skeletal muscles (32, 52) . Previous studies have confirmed that myostatin promotes the upregulation of atrogin-1 during skeletal muscle wasting (35, 36, 42, 59) . The molecular targets of atrogin-1 in the basal and myostatin-induced wasting conditions, however, have yet to be explored. Thus, using the atrogin-1-CTAP vector, we coimmunoprecipitated the atrogin-1 complex in control and hMstn-treated C2C12 myotubes and identified the proteins bound to atrogin-1 using nano-LC-MS/MS (Fig. 5A) . It must be noted that hMstn-treated C2C12 myotubes stably expressing atrogin-1-CTAP or empty vector were undergoing atrophy because we observed reduced protein levels of Myh (Fig. 5A) . We found 50 proteins that were associated with the atrogin-1-CTAP construct in control (Fig. 5B) . Conversely, 93 proteins interacted with the atrogin-1 coimmunoprecipitated complex in hMstn-treated C2C12 myotubes (Fig. 5B and Table 1 ). We observed that 41 atrogin-1-associated proteins were common to both the control and the hMstn-treated C2C12 myotubes (Fig.  5B) . While only 9 proteins were unique to the control, 52 proteins were specific to the hMstn-treated myotubes (Fig. 5B) . Further- more, we have also noticed elevated amounts of ubiquitinated substrates in the hMstn-treated atrogin-1-CTAP coimmunoprecipitated complex compared with the atrogin-1-CTAP complex collected from control myotubes (Fig. 5C ).
In C2C12 myotubes, the most prominent atrogin-1 interactors in the two conditions were cytoskeletal proteins (Fig. 5, D  and E) . The number of atrogin-1-associated cytoskeletal components during hMstn treatment was twice that of the control ( Fig. 5, D and E, and Tables 1-4) . String version 8.3 clustering of the atrogin-1-associated proteins reflected this characteristic association of several sarcomeric proteins, including the Myh and myosin light chain (Myl) isoforms (Fig. 6, A and B, and Table 4 ). While these sarcomeric proteins interacted with atrogin-1 during control (Fig. 6A) , it was interesting to notice the increased variety of such components interacting with the atrogin-1 in the presence of hMstn, particularly Des and Vim (Fig. 6B) .
Functional classification of the atrogin-1-associating proteins by KEGG demonstrated that atrogin-1-CTAP interacts with various enzymes involved in glycolysis and gluconeogenesis (data not shown). For instance, the atrogin-1-CTAP coimmunoprecipitated complexes isolated from the control and the hMstn-treated cells associated with fructose-bisphosphatase aldolase, pyruvate kinase, and malate dehydrogenase (Table 2 and data not shown). Glyceraldehyde 3-phosphate dehydrogenase was bound to atrogin-1-CTAP exclusively in hMstntreated C2C12 myotubes ( Table 1 ). The association of the F-type H ϩ transporting ATPase subunit with atrogin-1 in the control and hMstn-induced myotubes was also noted (Table 1) .
Atrogin-1 associated with Des and Vim in differentiated myotubes during hMstn treatment. As we reported previously, atrogin-1 upregulation during hMstn treatment resulted in the increased ubiquitin-mediated proteolysis of Myh and Myl both in murine and in human muscle cell cultures (35, 36) . According to Table 1 , we also identified two more sarcomeric proteins, Des and Vim, which were exclusive to the atrogin-1- Fig. 5 . Atrogin-1 increasingly interacts with cytoskeletal, nuclear, and cytoplasmic proteins in C2C12 myotubes exposed to hMstn. A: the image represents a silver-stained 4 -12% NuPAGE gel of the purified atrogin-1-CTAP protein complex from C2C12 myotubes treated with or without hMstn. Immunoblot of Myh for C2C12 myotubes stably expressing atrogin-1-CTAP treated with or without hMstn is shown. Tubulin levels were assessed to ensure equal loading. B: Venn diagram highlights the number of atrogin-1-associated proteins that were shared or unique to the control and hMstn-treated C2C12 myotubes. The number of atrogin-1-interacting proteins in the control was 50. The number of atrogin-1-associated proteins in the myostatin-exposed myotubes was 93. C: immunoblot analysis of polyubiquitinated proteins (Ubi) associated with atrogin-1-CTAP in untreated and hMstn-treated C2C12 myotubes. D and E: atrogin-1-associated proteins identified from untreated C2C12 myotubes (D) and hMstn-treated C2C12 myotubes (E) classified according to their subcellular location. Subcellular localization was classified by MGI Gene Ontology (GO)_Slim Chart Tool. CTAP coimmunoprecipitated complex isolated from C2C12 myotubes treated with hMstn. The treatment of differentiated C2C12 myotubes with hMstn for 24 h resulted in the reduced protein levels of both Des and Vim compared with the untreated control (Fig. 7A) . Furthermore, to confirm that the reduced expression levels of Des and Vim were due to ubiquitin-mediated proteolysis, we immunoprecipitated the two sarcomeric proteins and immunoblotted for polyubiquitin. Expectedly, immunoprecipitated Des and Vim collected from differentiated C2C12 myotubes treated with hMstn demonstrated a greater degree of polyubiquitination compared with the untreated control (Fig. 7, B and C) . Furthermore, elevated amounts of Des and Vim were observed in the coimmunoprecipitated atrogin-1-CTAP complex collected from hMstntreated differentiated C2C12 myotubes (Fig. 7, D and E) . To determine whether the absence of atrogin-1 prevented the hMstn-induced degradation of Des and Vim, atrogin-1 Ϫ/Ϫ and atrogin-1 ϩ/ϩ primary myoblasts were differentiated and subsequently treated with hMstn for 24 h. Immunoblot analysis detecting for Des and Vim demonstrated that hMstn-treated atrogin-1 Ϫ/Ϫ myotubes possessed greater quantities of the two sarcomeric proteins compared with hMstn-treated atrogin-1 ϩ/ϩ myotubes (Fig. 7E) , indicating that Des and Vim are two novel, bona fide substrates of atrogin-1.
DISCUSSION
Atrogin-1 is a muscle-specific E3 ligase inducible by the procachectic growth factor, myostatin. In this report, we have demonstrated that myostatin signals through atrogin-1 to regulate MyoD levels and thereby modulate myogenesis. We have also characterized the substrates of atrogin-1 in myoblasts and myotubes and have highlighted that several nuclear, cytoplasmic, mitochondrial, and structural proteins are associated with atrogin-1 and are potentially degraded by the ubiquitin-proteasome system in response to myostatin (Fig. 8) .
Myostatin signals via atrogin-1 to regulate myogenesis. Myostatin regulates myoblast cell cycle progression and differentiation (32, 33, 38, 40) . According to the published literature, elevated amounts of myostatin were also detected in quiescent satellite cells (18) . Myostatin expression markedly decreases upon satellite cell activation, hence affirming the role of this negative growth factor in modulating muscle regeneration (18, 41) . Of the numerous routes through which myostatin negatively influences muscle development, MyoD downregulation by myostatin has garnered the most attention as this transcription factor not only controls the cell cycle exit of myoblasts but also facilitates myoblast differentiation by the selective expression of muscle-specific genes (7, 8) .
While MyoD expression can be regulated at the transcriptional level, posttranslational modifications, including phosphorylation and ubiquitination, modulate MyoD activity in response to atrophic conditions (1, 30, 40, 53) . Indeed, several publications have established that atrogin-1 interacts with MyoD, and this particular association is elevated during muscle wasting conditions (30, 51, 53) . However, the molecular signals that enhance MyoD-atrogin-1 association and the resulting proteolytic degradation of the myogenic regulatory factor are not fully known. Given that myostatin promotes the expression of atrogin-1, we speculated that myostatin itself could induce atrogin-1-mediated MyoD interaction and degradation. Indeed, our results demonstrate that atrogin-1 increasingly associates with MyoD in C2C12 differentiating myotubes when challenged with hMstn ( Fig. 1, E and F) . If atrogin-1 tethers myostatin signaling to the targeting of MyoD for degradation, then the absence of the muscle-specific E3 ligase may nullify the negative growth effects conferred by myostatin. Consistent with this hypothesis, treating atrogin-1 Ϫ/Ϫ differentiating myotubes with hMstn did not result in the precipitous decline of MyoD levels compared with control differentiating myotubes similarly exposed to hMstn, thus providing further credibility to the myostatin-atrogin-1-MyoD axis in regulating myogenesis (Fig. 2, A-D) . In addition to myogenic differentiation, we also have demonstrated that hMstn-induced upregulation of atrogin-1 further limits myoblast proliferation (Fig. 2E) . While hMstn addition significantly curtailed wildtype myoblast proliferation rates, atrogin-1 Ϫ/Ϫ myoblast proliferation was almost completely unaffected by the negative growth effects of hMstn (Fig. 2E) . The involvement of 
Vim vimentin ϩ atrogin-1 in regulating myoblast proliferation would suggest another potential regulatory pathway of myoblast growth, though its specific role would require further investigation. Atrogin-1 targets several intracellular proteins in response to myostatin signaling. Myostatin overexpression as a consequence of pathological conditions, such as cancer cachexia, chronic renal failure, disuse atrophy and denervation leads to severe skeletal muscle wasting (43, 60) . Atrogin-1 and another muscle-specific E3 ligase, MuRF1, are well-characterized facilitators of myostatin-induced skeletal muscle wasting (35, 36, 42) . Recently, several groups have reported that atrogin-1 directly targets MyoD and eIF3-f (16, 30, 44) , hence indicating that this muscle-specific E3 ligase promotes muscle wasting by principally impairing protein synthesis and muscle regeneration. MuRF1, on the other hand, expedites the wasting of skeletal muscle by selectively targeting and degrading sarcomeric proteins through the ubiquitin-proteasome pathway (14, 15) . Along with increased proteolysis, skeletal muscle wasting manifested by myostatin is also a result of depressed protein synthesis (35, 36) . Indeed, prior publications have demonstrated that myostatin exposure ablates IGF-I/PI3K/Akt signaling, a potent signaling cascade that stimulates hypertrophy in skeletal muscles (2, 28, 34 -36, 42, 46, 55,  57) . As mentioned previously, atrogin-1 overexpression reduces protein synthesis by ubiquitination and degrading eIF3-f, a component of the translational machinery. In this report, we found a noticeable cluster of protein synthesis components comprising other proteins of the eIF2/3/4 complexes, elongation factors, such as Eef1, and ribosomal components (Figs. 4 and 6) . The direct or indirect association of such translational components with atrogin-1 was pronounced in myoblasts, but limited in myotubes (Figs. 4 and 6) . Hence, in addition to reduced MyoD expression, we could surmise that the impaired myogenicity of myoblasts exposed to hMstn might be aggravated by the reduced protein synthesis of critical myogenic proteins required for muscle differentiation.
Surprisingly, the characterization of atrogin-1-associated proteins by nano-LC-MS/MS in both control and hMstntreated C2C12 myotubes revealed the interaction of several sarcomeric and structural proteins (Tables 1-4) . Moreover, the number and variety of these sarcomeric and structural proteins interacting with atrogin-1 were more apparent in the myostatininduced condition (Tables 1-4 ). Published data from our laboratory have validated that atrogin-1 ubiquitinates all isoforms of the myosin heavy and light chains (35) . On the basis of these observations, we suggest that atrogin-1 association to myofibrillar proteins in control might serve a homeostatic or housekeeping function. However, atrogin-1 overexpression as a corollary of myostatin exposure would give way to the excessive proteolysis of such myofibrillar proteins, thus exacerbating skeletal muscle wasting. Interestingly, we discovered the association of Des and Vim in the atrogin-1-CTAP coimmunoprecipitated complex solely in C2C12 myotubes treated with hMstn (Fig. 7, D and E, and Table 1) . A recent study has demonstrated that the ectopic overexpression of myostatin in rat skeletal muscle resulted in reduced levels of Des protein (19) . Furthermore, treatment of wild-type primary myotubes (atrogin-1 ϩ/ϩ ) with hMstn resulted in the loss of both Des and Vim (Fig. 7F) . Contrastingly, atrogin-1 Ϫ/Ϫ primary myotubes treated with hMstn did not show any reduction in Des and Vim protein amounts (Fig. 7F) . Thus, these results suggest that Des and Vim are targets of atrogin-1 during myostatin treatment. Moreover, the functional loss of Des through deletions or mutations has been linked to Des-related myopathies (21, 37) , and it is possible that atrogin-1 may have a role in the onset of these pathologies. Although several reports have extensively documented the expression state of vimentin in muscular dystrophy (5, 6, 13, 23) , we were unable to find the loss of vimentin protein levels in other models of skeletal muscle wasting. Here we provide preliminary evidence that myostatin may also induce further disruptions to the intermediate filaments by promoting the degradation of vimentin through atrogin-1 (Fig. 7) .
The targets of atrogin-1 are not exclusive to myofibrillar proteins. Rather, we have demonstrated that atrogin-1 interacts and may potentially degrade a myriad of cellular components from the cytosol, nucleus, and mitochondrion (Table 3) . Atrogin-1 from C2C12 myotubes in the control and myostatin-treated condition was associated with several cytosolic enzymes involved in glycolysis and gluconeogenesis, such as pyruvate kinase and malate dehydrogenase (Tables 1 and 3 ). Owing to the limitations of nano-LC-MS/MS, we were unable to quantify whether there was an increased association of such components of metabolic machinery with atrogin-1 during myostatin treatment. Moreover, it must be noted that due to the native conditions of atrogin-1-CTAP coimmunoprecipitation procedure, other interactors of atrogin-1 detected in our analysis might not be directly associated with muscle-specific E3 ligase. As such, detailed studies characterizing bona fide atrogin-1-associated proteins should be undertaken.
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